Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom Macroglobulinemia

Explore clinical trials studying Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

397 public trials 44 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom Macroglobulinemia trial results

Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

NCT05640102

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • South Alabama Medical Science Foundation Mitchell Cancer Institute Mobile, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Los Angeles Cancer Network (Lacn) Glendale, California, United States
View Trial Details
Recruiting

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

NCT06708897

Conditions
Blood Protein Disorders, CLL (Chronic Lymphocytic Leukemia), CLL / SLL, +32 more
Locations
  • Norton Cancer Institute, St. Matthews Campus Louisville, Kentucky, United States
  • University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • University of Cincinnati Cincinnati, Ohio, United States
  • The Ohio State University Columbus, Ohio, United States
View Trial Details
Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Conditions
Blood Protein Disorders, Bronchial Diseases, Bronchiolitis, +43 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • University of California San Diego Medical Center La Jolla, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • St. Joseph Hospital Center for Cancer Prevention and Treatment Orange, California, United States
View all 175 locations
View Trial Details
Recruiting

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

NCT07424833

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +33 more
Locations
  • Mayo Clinic Jacksonville, Florida, United States
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • START Los Angele Los Angeles, California, United States
  • START Midwest Grand Rapids, Michigan, United States
View Trial Details
Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +37 more
Locations
  • City of Hope Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 62 locations
View Trial Details

Related conditions